- Home
- LBGJ vs LSTA Comparison
LBGJ vs LSTA Comparison
Compare LBGJ & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBGJ
- LSTA
- Stock Information
- Founded
- LBGJ 2007
- LSTA 1980
- Country
- LBGJ China
- LSTA United States
- Employees
- LBGJ N/A
- LSTA N/A
- Industry
- LBGJ
- LSTA Misc Health and Biotechnology Services
- Sector
- LBGJ
- LSTA Health Care
- Exchange
- LBGJ NYSE
- LSTA Nasdaq
- Market Cap
- LBGJ 24.7M
- LSTA 23.1M
- IPO Year
- LBGJ 2024
- LSTA N/A
- Fundamental
- Price
- LBGJ $1.44
- LSTA $2.57
- Analyst Decision
- LBGJ
- LSTA Strong Buy
- Analyst Count
- LBGJ 0
- LSTA 2
- Target Price
- LBGJ N/A
- LSTA $23.50
- AVG Volume (30 Days)
- LBGJ 24.1K
- LSTA 55.4K
- Earning Date
- LBGJ 08-15-2025
- LSTA 08-11-2025
- Dividend Yield
- LBGJ N/A
- LSTA N/A
- EPS Growth
- LBGJ N/A
- LSTA N/A
- EPS
- LBGJ N/A
- LSTA N/A
- Revenue
- LBGJ $11,781,015.00
- LSTA $1,000,000.00
- Revenue This Year
- LBGJ N/A
- LSTA N/A
- Revenue Next Year
- LBGJ N/A
- LSTA N/A
- P/E Ratio
- LBGJ N/A
- LSTA N/A
- Revenue Growth
- LBGJ 21.82
- LSTA N/A
- 52 Week Low
- LBGJ $1.02
- LSTA $1.87
- 52 Week High
- LBGJ $5.50
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- LBGJ N/A
- LSTA 47.58
- Support Level
- LBGJ N/A
- LSTA $2.45
- Resistance Level
- LBGJ N/A
- LSTA $2.80
- Average True Range (ATR)
- LBGJ 0.00
- LSTA 0.22
- MACD
- LBGJ 0.00
- LSTA -0.01
- Stochastic Oscillator
- LBGJ 0.00
- LSTA 37.35
About LBGJ LI BANG INTERNATIONAL CORPORATION I
Li Bang International Corp Inc is a holding company. The firm through its subsidiaries engages in designing, developing, producing, and selling stainless steel commercial kitchen equipment in China under its own Libang brand. In addition, its subsidiaries provide customers with comprehensive services, from commercial kitchen design in the early stage to equipment installation and after-sales maintenance.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.